Progyny News

Barclays Sticks to Its Buy Rating for Progyny (PGNY)

TipRanksMay 20 17:50

Progyny Is Maintained at Buy by Truist Securities

Progyny Is Maintained at Buy by Truist Securities

Dow JonesMay 17 20:37

Truist Securities: Maintaining the Progyny (PGNY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $46.00 to $37.00.

Truist Securities: Maintaining the Progyny (PGNY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $46.00 to $37.00.

Zhitong FinanceMay 17 20:31

Truist Securities Cuts Price Target on Progyny to $37 From $46, Keeps Buy Rating

Progyny (PGNY) has an average rating of buy and price targets ranging from $30 to $48, according to analysts polled by Capital IQ. Price: 27.15, Change: -0.40, Percent Change: -1.45

MT NewswiresMay 17 17:27

Progyny Price Target Maintained With a $48.00/Share by Cantor Fitzgerald

Progyny Price Target Maintained With a $48.00/Share by Cantor Fitzgerald

Dow JonesMay 17 01:43

Cantor Fitzgerald Reiterates Overweight on Progyny, Maintains $48 Price Target

Cantor Fitzgerald analyst Sarah James reiterates Progyny (NASDAQ:PGNY) with a Overweight and maintains $48 price target.

BenzingaMay 17 01:32

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Arvinas Holding Company (ARVN) and Progyny (PGNY)

TipRanksMay 17 00:40

Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Progyny's executives will participate in a

GlobeNewswireMay 14 23:00

Analysts' Top Healthcare Picks: Xenon (XENE), Progyny (PGNY)

TipRanksMay 14 20:30

Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays

Progyny Price Target Cut to $30.00/Share From $48.00 by Barclays

Dow JonesMay 14 02:05

Progyny Is Maintained at Overweight by Barclays

Progyny Is Maintained at Overweight by Barclays

Dow JonesMay 14 02:05

Barclays Maintains Overweight on Progyny, Lowers Price Target to $30

Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and lowers the price target from $48 to $30.

BenzingaMay 14 01:54

Progyny (NASDAQ:PGNY) Has More To Do To Multiply In Value Going Forward

Yahoo FinanceMay 13 18:31

Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)

TipRanksMay 13 09:20

Fertility Solutions-Focused Progyny Stock Sinks After Soft Guidance; Analyst Says 'Can No Longer Underwrite Sustained Healthy Growth In Forecasts'

On Thursday, Progyny Inc (NASDAQ:PGNY) reported first-quarter sales of $278.1 million, up 7.6% year over year, missing the consensus of $289.46 million, primarily due to the increased number of client

BenzingaMay 11 02:42

Progyny Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 37.96% Canaccord Genuity $46 → $37 Maintains Buy 05/10/2024 52.87% BTIG $50 → $41 Maintains Buy

BenzingaMay 11 02:42

Top Midday Decliners

MacroGenics (MGNX) plummeted past 75% amid heavy trading after the company said five patients died in an ongoing mid-stage study of its experimental drug to treat a type of prostate cancer. BMO downgr

MT NewswiresMay 11 02:01

Progyny Inc (PGNY) Q1 2024 Earnings: Mixed Results Amid Market Challenges

Yahoo FinanceMay 11 01:20

Progyny Price Target Cut to $41.00/Share From $50.00 by BTIG

Progyny Price Target Cut to $41.00/Share From $50.00 by BTIG

Dow JonesMay 10 23:08

Progyny Is Maintained at Buy by BTIG

Progyny Is Maintained at Buy by BTIG

Dow JonesMay 10 23:08